Nurosene’s NetraAI technology was successful in self-generating hypotheses from proprietary data sets that will accelerate clinical trials and help build Nurosene’s IP portfolio.
Nov. 23, 2021
/CNW/ – Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (
: 8TV) (OTC: MNNDF), a healthtech company focused on building a generation of better brains, today announced that it has released preliminary findings that will enable significantly increased efficiency in the development of anti-aging therapeutics.
Nurosene utilized an age-related data set that was derived from skin samples of those very young to elderly people to create proprietary data and self-generated insights that will enhance Nurosene’s IP portfolio. The NetraAI technology was also able to derive several meaningful and novel biological mechanisms at play in aging, which will enhance Nurosene’s active longevity study program.
“NetraAI has demonstrated that it can transform data into powerful insights, which is the basis for these preliminary findings. It’s like having a robot scientist in the lab that teaches me things about different diseases. Our system is teaching us how to improve clinical trials and create novel drugs,” said Chief Scientific Officer, Dr.
Nurosene will leverage these results to continue to expand its IP portfolio and attract partnerships with leading biotech and pharmaceutical companies. There is significant interest in the NetraAI technology that accelerates the path towards novel therapeutics through a clearer map of the aging space.
“It’s amazing to see a machine consume a data set with an imprecise label, and then come back with precise insights about mitochondria, telomeres, and bio electric characteristics that affect regenerative capacities and longevity in numerous species and organisms throughout biology. This enables us to look at mechanisms of aging that go way beyond the original label in an accurate, knowledge producing way,” said Chief Innovation Officer,
Until now, machine learning has generally been able to make predictions but Nurosene is focused on building a system that combines AI, biology, and chemistry in order to find insights that go beyond what we already know. Nurosene has proven technology that not only develops predictive models with machine learning, but also generates new and actionable recommendations and hypotheses about diseases that go beyond what is currently known.
Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.
For more information, visit
NetraMark Corp., an AI and pharma-tech company, has developed proprietary solutions for pharmaceutical and biotechnology companies. These solutions allow them to leverage small to large data sets in order to optimize clinical trials and drug development. This is accomplished by providing a superior understanding of their patient populations and these insights are also used to develop new drugs and nutraceuticals. NetraMark is a wholly owned subsidiary of Nurosene Health Inc.
For more information, visit
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which is based upon Nurosene’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company’s activities in partnership with NetraMark and its NetraAI technology, as well as growth and other initiatives thereto.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene’s Final Long Form Prospectus dated
May 20, 2021
and filed with the applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in Nurosene’s Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
View original content to download multimedia: